61 results about "Bevacizumab" patented technology

The invention belongs to the technical field of medical diagnosis, and discloses a marker for evaluating the curative effect of treating hepatocellular carcinoma by combining TACE with Czodili monoclonal antibody and bevacizumab, and a construction method and application of an FAAP prognostic scoring model. The invention develops and verifies an FAAP prognostic scoring system, and a novel composite model integrates four indexes of fibrin degradation product / cholinesterase ratio * 1000 (FCR), aspartate aminotransferase (AST), alpha fetoprotein (AFP) and portal vein tumor thrombus (PVTT), and is used for predicting the survival condition of uHCC patients subjected to TACE-Czodimab-bevacizumab triple therapy. The tool has an instant clinical value, can optimize patient selection, guides adaptive treatment upgrading, and provides a standardized curative effect evaluation basis for a clinical test for exploring a TACE-immunotherapy-anti-angiogenesis combined scheme.

The invention belongs to the field of protein purification, and relates to a method for preparing bevacizumab, which comprises the steps of affinity chromatography, virus inactivation, deep filtration, composite anion exchange chromatography, cation exchange chromatography and the like.

The present application relates to the technical field of medicine, in particular to the application of gansix triol A in the preparation of a drug for treating gastric cancer and / or non-small cell lung cancer, gansix triol A plays an anti-gastric cancer role by selectively inhibiting the proliferation of gastric cancer MGC-803 cells and inhibiting angiogenesis, the mechanism involves inhibiting the VEGF / VEGFR2 signal pathway and inducing cell apoptosis; the mechanism of gansix triol A in inhibiting the VEGF / VEGFR2 signal pathway is similar to that of bevacizumab; gansix triol A plays an anti-non-small cell lung cancer role by selectively inhibiting the proliferation of non-small cell lung cancer A549 cells, the mechanism involves inhibiting the MAPK / ERK signal pathway and inducing cell apoptosis. The present application finds that the cytotoxic activity of gansix triol A on MGC-803 cells and A549 cells is significantly stronger than that of tanshinone IIA; gansix triol A has an anti-tumor effect of "one drug with double targets, double inhibition" and "high efficiency and low toxicity".

The invention relates to the technical field of biological medicines, and particularly discloses an application of Dehydrovomigol sensitized bevacizumab in treatment of cervical cancer. The invention further relates to a preparation method of the Dehydrovomigol sensitized bevacizumab. Compared with a bevacizumab single drug, the effect of the bevacizumab on growth and proliferation inhibition, invasion blocking and angiogenesis inhibition of cervical cancer cells can be remarkably enhanced by combining the Dehydrovomifolol, and the drug resistance of the bevacizumab is reversed. In different experimental models, the Q value of the combination scheme is greater than or equal to 1.15, and the stable synergistic anti-cervical cancer effect is shown. Dehydrovomifolol realizes the effect of enhancing the anti-cervical cancer activity of the bevacizumab by virtue of triple mechanisms of reversing drug resistance, enhancing anti-angiogenesis and regulating an immune microenvironment. According to the combination scheme, the anti-cervical cancer curative effect can be improved, the clinical medication dosage of bevacizumab is reduced, the occurrence risk of toxic and side effects such as hypertension and proteinuria is reduced, and a novel, safe and efficient treatment strategy is provided for cervical cancer treatment.

Provided include methods, compositions and kits for treating metastatic cancer in a subject. The method can comprise administering to a metastatic colorectal cancer patient an effective amount of a PLK1 inhibitor (for example, onvansertib) and an effective amount of bevacizumab, wherein the patient has not received any treatment comprising bevacizumab within at least three months prior to the administration of the PLK1 inhibitor and bevacizumab in a manner sufficient to reduce or inhibit progression of the metastatic cancer.

Provided herein are compositions and methods of using a Mu opioid receptor (MOR) antagonist (e.g. axelopran) alone or in combination with checkpoint inhibitor (such as e.g. an inhibitor of the PD-1 / PD-L1 pathway (e.g. an antibody such e.g. pem-brolizumab)) and / or an inhibitor of VEGF (e.g. bevacizumab) for reducing angiogenesis or treating cancer. Also provided herein are kits containing a MOR antagonist (e.g. axelopran) alone or in combination with checkpoint inhibitor and / or an inhibitor of VEGF for reducing angiogenesis or treating cancer.

The invention provides a nano embolism microsphere based on a magnetocaloric effect and a preparation method and application thereof, and relates to the field of medicines. According to the nano embolization microsphere, mesoporous ferroferric oxide is used as a carrier, and rificiguat and bevacizumab are loaded at the same time. The preparation method has the beneficial effects that the magnetic nano embolism microsphere system is constructed for the first time and is combined with the magnetocaloric effect; according to the invention, the embolism system of the magnetic nano-microsphere loaded rificiguat and bevacizumab is constructed for the first time; compared with an embolism agent for independently embolizing the blood vessel, the nano embolism microsphere disclosed by the invention also plays a role in killing residual tumor cells; compared with an uncontrollable embolism agent, the nano embolism microsphere disclosed by the invention can be used for accelerating drug release in an alternating magnetic field and a slightly acidic environment.

The invention provides a method for detecting the drug concentration of bevacizumab. The method comprises the following steps: taking a solution containing infliximab as an internal standard working solution, and determining the drug concentration of the bevacizumab in a sample to be detected by adopting liquid chromatography-tandem mass spectrometry. In drug monitoring for clinical detection of the bevacizumab concentration in human plasma, infliximab is adopted as an internal standard, the detection requirement can be effectively met, and the detection cost is reduced. The infliximab serves as an internal standard, methodological requirements of the established method can be met, and accuracy and reliability of detection results are ensured. In addition, by optimizing the sample pretreatment process, the operation steps are simplified, the detection time is shortened, manual operation errors are reduced, and the detection accuracy and efficiency are further improved.

Provided is a use of an anti-PD-1 antibody combined with a chemotherapeutic agent in the treatment of tumors such as cervical cancer or endometrial cancer. In some embodiments, the chemotherapeutic agent comprises a taxane drug and / or a platinum drug. In some embodiments, the use further comprises a use of the anti-PD-1 antibody combined with bevacizumab.

A single-cell transcriptome-guided multimodal synergistic injectable magnetically responsive biomimetic hydrogel system, its preparation method, and its application are described. This hydrogel platform is a three-level composite system of "matrix-microsphere-nanoparticle": the primary structure is a photocrosslinked methacryloyl hyaluronic acid three-dimensional network matrix; the secondary structure is GelMA microspheres loaded with MTPT nanoparticles prepared by microfluidic control; and the tertiary structure consists of bevacizumab and magnetite nanoparticles dispersed in the HAMA matrix. The MTPT nanoparticles have a mesoporous silica core, which is sequentially coated with temozolomide, a polydopamine coating, and a T7 targeting peptide. Under the activation of an alternating magnetic field, Fe3O4 generates a magnetothermal effect, which not only achieves local hyperthermia but also accelerates the time-sequential release of bevacizumab and MTPT, synergistically exerting the effects of chemotherapy, anti-angiogenic therapy, and hyperthermia.

To provide pharmaceutical compositions for treating solid tumor, in particular, glioblastoma multiforme (GBM).SOLUTION: Provided herein is a pharmaceutical composition for use in a method for retarding progression of brain tumor, where the composition comprises a therapeutical effective dose of F16, that is, isoindole (1, 3-dioxy-2, 3-dihydro-1H-isoindol-4-yl)-amide and a therapeutically effective dose of a chemotherapeutic agent in a pharmaceutical carrier, where the brain tumor is glioblastoma multiforme, and the chemotherapeutic agent is temozolomide (TMZ) or bevacizumab (BVZ) or similar agent.SELECTED DRAWING: Figure 1

The invention belongs to the technical field of medicines, and particularly relates to a novel method for relieving toxic and side effects of bevacizumab. Based on preclinical research, the combination of glutathione and bevacizumab relieves toxic and side effects on immune cells when bevacizumab is independently used. Experimental data comparison shows that compared with bevacizumab single drug treatment, the combined glutathione can significantly reduce the inhibition effect on immune cell activity, so that the cell proliferation activity is repaired, and meanwhile, the disordered cell cycle and the abnormally expressed cell factor level tend to be normalized. The invention provides a novel treatment scheme and thought for targeted treatment of tumor patients with the VEGF monoclonal antibody bevacizumab, is also beneficial to research on the toxic action mechanism of drugs and optimization of the treatment scheme, and has important potential clinical experimental research value.

The application discloses a BICI scoring system for predicting the curative effect of immunotherapy for metastatic colorectal cancer and application thereof, and belongs to the technical field of biological medicine. The BICI scoring system is based on immunohistochemical detection, integrates four dimensions of angiogenesis, immune checkpoints, TGF-beta signal and immune activation, and is calculated by a formula IHC-BICI=VEGFA+PD-L2+TGFB1x2-CD8 score. Taking 4 points as a cut point, BICI-High and BICI-Low are divided, and a bevacizumab combined with an immune checkpoint inhibitor treatment benefit population is accurately screened. The application also discloses a detection kit containing four specific antibodies, application thereof and a treatment decision method. The scoring system of the application only needs conventional IHC detection, has low cost, excellent prediction effect, is suitable for second-line and above treatment and clinical stratification of MSS / pMMR type metastatic colorectal cancer, and has important clinical application value.

Provided herein are combination therapies comprising a KRasG12C inhibitor (e.g. Compound 1 or a pharmaceutically acceptable salt thereof) and a VEGF antagonist (e.g., bevacizumab) and methods of using such combination therapies.

The present invention belongs to the technical field of hydrogel preparations, and specifically relates to a dual-responsive hydrogel, a preparation method, and an application thereof. The present invention synthesizes a cross-linked polycationic hydrogel composed of phenylboronic acid-modified sodium alginate, a protocatechuic acid-polyethyleneimine graft polymer, and bevacizumab sustained-release nanoparticles, referred to as a dual-responsive OSPPB hydrogel. This hydrogel blocks neurovascularization at the osteochondral interface by locally clearing extracellular RNA and releasing bevacizumab, thereby alleviating OA pain and disease progression.

To provide an ophthalmic composition of bevacizumab.SOLUTION: Provided is an ophthalmic composition of bevacizumab; a. herein, the limit of Bacterial Endotoxins Test (BET) is within the range of 0.001 to 0.4EU / mg, preferably within the range of 0.001 to 0.2Eu / mg, and more preferably within the range of 0.001 to 0.16Eu / mg; b. herein, a particulate substance is as follows; 1 to 50 particles≥diameter 10 μm per iv.ml, 0 to 5 particles≥diameter 25 μm per v.ml, and 0 to 2 particles≥diameter 50 μm per vi.ml; and c. herein, the composition has an aggregate of 0.1 to 5%, more preferably 0.1 to 4%, and most preferably 0.1 to 3.5% for 2 to 3 years, preferably for 2 to 2.5 years, and most preferably for 2 years.SELECTED DRAWING: None

To provide effective cancer treatments. [Solution] The present invention provides a cancer treatment method that combines a CD47 inhibitor, an immune checkpoint inhibitor (e.g., an anti-PD-1 antibody), and standard therapy (e.g., combination therapy of FOLFOX therapy with bevacizumab or cetuximab for unresectable advanced or recurrent colorectal cancer, or FOLFIRINOX therapy or a reduced-dose regimen for pancreatic cancer with distant metastases).

Disclosed are kits and methods for detecting whether a patient with metastatic colorectal cancer should receive AVASTIN® (bevacizumab) in addition to chemotherapy.

The application provides application of bevacizumab in preparation of a medicine for inhibiting hemorrhagic lesions of cerebral vascular malformations, and belongs to the technical field of medicine application. The application firstly discovers and proves by experiments that bevacizumab can be used for binding free VEGF molecules in serum of a patient with a cavernous cerebral vascular malformation, thereby inhibiting a VEGF path, and having obvious inhibiting effect on symptomatic hemorrhagic lesions of the cavernous cerebral vascular malformation, and developing a new use of bevacizumab, and providing a new selection of drug treatment for the patient with the cavernous cerebral vascular malformation.

The invention discloses a drug-loaded microgel-gel sustained-release dressing as well as a preparation method and application of the drug-loaded microgel-gel sustained-release dressing. The dressing comprises a drug microgel phase loaded by GelMA microspheres and a hydrogel shell phase formed by copolymerizing CSMA and a double-bond-containing micromolecule cross-linking agent, and can be polymerized and cured in situ through ultraviolet light. The carried medicine comprises one of bevacizumab, triamcinolone acetonide and fluorouracil, and multi-medicine synergistic slow release is achieved. The dressing provided by the invention has good biocompatibility, degradability, shape adaptability and slow release performance, can significantly improve local drug concentration, reduce administration frequency and improve patient compliance, and is suitable for treatment and repair of keloid.

The invention relates to the field of biological medicine, discloses application of UCHL1 in preparation of a detection product for predicting the curative effect and prognosis of a hepatocellular carcinoma atelizumab combined with bevacizumab, and further discloses a kit for predicting the curative effect and prognosis of the hepatocellular carcinoma atelizumab combined with bevacizumab. The UCHL1-based kit disclosed by the invention can be used as a curative effect prediction tool for Atezo / Bev immune combined treatment, provides precise treatment guidance for HCC patients, and improves the individualized treatment level.

Circulating tumor DNA (ctDNA) is a promising non-invasive biomarker in cancer. The inventors aim to assess the dynamic evolution of ctDNA in patients with hepatocellular carcinoma (HCC). For that, they analyzed 772 plasmas from 173 patients with HCC collected at the time of diagnosis or treatment (n=502), 24h after locoregional treatment (n=154), and during follow-up (n=116). All samples were analyzed for cell free DNA (cfDNA) concentration, and for mutations in TERT promoter, CTNNB1, TP53, PIK3CA and NFE2L2 by sequencing and droplet-based digital PCR. Results were compared to 232 corresponding tumor samples. In active HCC, the inventors identified 27-5% of mutations in TERT promoter, 21 -3% in TP53, 13- 1% in CTNNB1, 0-4% in PIK3CA and 0-2% in NFE2L2, most of the times similar to those identified in the corresponding tumor. In 103 patients treated by percutaneous ablation, the presence and number of mutations in the ctDNA before treatment were associated with higher risk of death (p=0 001 ) and recurrence (p<0 001). In patients treated by atezolizumab / bevacizumab, persistence of mutation in ctDNA was associated with radiological progression (63-6% versus 36-4% for disappearance, p=0 019). Thus, circulating tumor DNA offers dynamic information reflecting tumor biology and represents a non-invasive tool useful to guide HCC clinical management.

A system and method for a dry formulation of bevacizumab are provided. The dry formulation comprises bevacizumab, a heat stabilizer, and a buffer salt, wherein bevacizumab is contained in the dry formulation in a range of 50% to 90% by weight. A method for preparing an injectable formulation of bevacizumab comprises the steps of: preparing a spray-drying solution comprising bevacizumab, a buffer salt, and a heat stabilizer; spray-drying the spray-drying solution to obtain a dry formulation containing bevacizumab in a range of 50% to 90% by weight; and storing the dry formulation for reconstitution or resuspension with a carrier to form an injectable formulation for one or more of subcutaneous, intramuscular, ocular, and intravenous injection.

The invention belongs to the technical field of organ-like models, and particularly discloses an FET vascularized colorectal cancer organ-like model for evaluating the treatment effect of bevacizumab. The FET vascularized colorectal cancer organoid model is formed by co-culturing human colorectal cancer organoid, vascular endothelial cells (HUVEC-GFP) and hepatic stellate cells (fibroblasts and simulated liver metastasis environment), and is constructed through the steps of separating the human colorectal cancer organoid, preparing a 3D culture support mixture, co-culturing the cells and dynamically culturing. By integrating vascular endothelial cells, hepatic stellate cells and a dynamic flow environment, the limitation of an existing model is overcome, and the treatment effect of bevacizumab is evaluated more accurately. By simulating physiological angiogenesis, liver metastasis microenvironment and hemodynamics, predictability and reliability of drug screening are improved.

The application provides a bevacizumab Fab antibody, a detection reagent and a preparation method and application thereof, and belongs to the technical field of drug detection. The bevacizumab Fab antibody comprises a coating antibody Beva-7E1 and an enzyme-labeled antibody Beva-6C11; the coating antibody Beva-7E1 is produced by a hybridoma cell strain Beva-7E1 (the preservation number is CGMCC No.46305), and the enzyme-labeled antibody Beva-6C11 is produced by a hybridoma cell strain Beva-6C11 (the preservation number is CGMCC No.46306). The bevacizumab Fab antibody and the detection reagent thereof can be used for detecting the free blood drug concentration of bevacizumab with high specificity, high sensitivity, simplicity, rapidness and high automation degree.

The invention focuses on developing final ophthalmic dosages based on Sildenafil associated with bevacizumab, known for its retino-protective properties, aimed to preserve and improve visual functions, particularly in patients with retinal degenerative disease specially for the dry form of macular degeneration

The invention provides a drug resistance marker of an anti-angiogenesis drug and application of the drug resistance marker, and particularly provides application of gamma-synuclein (SNCG) as the drug resistance marker of the anti-angiogenesis drug, especially bevacizumab.

Systems and methods are provided for a dried formulation of bevacizumab. The dried formulation comprises bevacizumab, a thermal stabilizer, and buffer salts, wherein the bevacizumab is included in the dried formulation in a range of from 50 wt.% to 90 wt.%. A method of preparing an injectable formulation of bevacizumab comprises: preparing a spray drying solution including the bevacizumab, buffer salts, and a thermal stabilizer; spray drying the spray drying solution to obtain a dried formulation comprising bevacizumab in a range of from 50 wt.% to 90 wt.%; and storing the dried formulation for reconstitution or resuspension with a carrier to form the injectable formulation for one or more of a subcutaneous, intramuscular, ocular, and intravenous injection.

Disclosed herein are compositions comprising nanoparticle complexes comprising albumin-bound paclitaxel and an anti-VEGF antibody, wherein the ratio of albumin-paclitaxel to antibody is between 2:1 and 1:25. Additionally disclosed herein are methods using the compositions of the present invention, such as for treating a VEGF-expressing cancer in a mammal, for example, skin cancer.

The application belongs to the field of protein purification, and relates to a method for preparing bevacizumab, comprising the steps of affinity chromatography, virus inactivation, deep filtration, composite anion exchange chromatography, cation exchange chromatography and the like.